Chris Ryan

May 13, 2022

Atezolizumab in conjunction with VB10.16, the first off-the-shelf therapeutic cancer vaccine, elicited encouraging responses in pretreated patients with HPV16-positive advanced cervical cancer.

March 10, 2022

Patients with HER2-negative, locally advanced or metastatic breast cancer have experienced improved survival rates both in real-world data and the phase 3 EMBRACA trial.

March 10, 2022

Although adjuvant neratinib was not found to improve progression-free or overall survival across a population of patients with glioblastoma, the agent yielded promising progression-free survival rates in a subset of patients with EGFR-positive disease.

February 08, 2022

Patients with treatment-naïve advanced gastrointestinal stromal tumors demonstrated promising responses following treatment with the TKI imatinib plus the MEK inhibitor binimetinib.

February 02, 2022

An expert with Stanford Health comments on the potential value of secondary cytoreductive surgery for patients with recurrent ovarian cancer and the need for careful patient selection when considering this treatment strategy.

January 21, 2022

Pembrolizumab plus chemotherapy did not induce clinically meaningful survival benefit, compared with chemotherapy alone, in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher.

January 16, 2022

Ibrutinib plus rituximab is effective, easy to administer, and removes the need for chemotherapy in older patients, say experts.

December 29, 2021

A comparative analysis indicated that lisocabtagene maraleucel generated superior quality of life in patients with relapsed/refractory large B-cell lymphoma compared with the current standard of care.

December 13, 2021

In comparison to physicians’ choice of treatment, ciltacabtagene autoleucel demonstrated significant advantages in progression-free and overall survival, time to next treatment, and overall response rate.

November 16, 2021

Trilaciclib was associated with reduced chemotherapy-induced myelosuppression and the need for associated supportive care in patients with a subtype of lung cancer.